|
|
|
| Clinical Efficacy and Survival Analysis of Tislelizumab Combined with Sunitinib in the Treatment of Metastatic Renal Cancer |
| WANG Mengjie, GUO Xiaofang |
| Department of Pharmacy, Shaanxi Provincial Cancer Hospital, Xi'an Shaanxi 710021 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy and survival outcomes of tislelizumab combined with sunitinib in the treatment of metastatic renal cancer.【Methods】 Forty-two patients with metastatic renal cancer were randomly divided into the observation group and the control group, with 21 patients in each group. The observation group was treated with oral sunitinib combined with intravenous tislelizumab, while the control group was treated with oral sunitinib combined with intravenous saline. After six treatment cycles, the efficacy, incidence of adverse reactions, and survival prognosis were compared between the two groups. Additionally, CD3+, CD4+, CD4+/CD8+, matrix metalloproteinase-2 (MMP-2), vascular endothelial growth factor (VEGF), and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels were measured before and after treatment and compared between the two groups.【Results】 The disease control rate in the observation group was 90.48%, which was significantly higher than that of 61.90% in the control group (P<0.05). After treatment, CD3+, CD4+, and CD4+/CD8+ levels increased in both groups, with the observation group showing higher levels than the control group (P<0.05). MMP-2, VEGF, and TIMP-1 levels decreased in both groups post-treatment, with lower levels in the observation group compared to the control group (P<0.05). The incidence of adverse reactions between the two groups showed no statistically significant difference (P>0.05). The median progression-free survival (PFS) was 11 months in the control group and 15 months in the observation group, with a statistically significant difference between the PFS curves of the two groups (P<0.05).【Conclusion】 Tislelizumab combined with sunitinib is effective and safe in the treatment of metastatic renal cancer.
|
|
Received: 28 September 2023
|
|
|
|
|
|
[1] XIONG W, ZHANG B, YU H X, et al. RRM2 regulates sensitivity to sunitinib and PD-1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway[J].Adv Sci (Weinh),2021,8(18):881.
[2] MSAOUELl P, GOSWAMI S, THALL P F, et al. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy[J].Sci Transl Med,2022,14(641):6420.
[3] 张兴明,曾宇皓,朱旭东,等. 根据血药浓度监测结果个性化调整舒尼替尼方案对转移性肾癌的安全性和疗效[J].中华泌尿外科杂志,2022,43(1):10-16.
[4] 陈美元,沈宏亮,佟昕,等. 替雷利珠单抗治疗局部晚期或转移性尿路上皮癌的疗效和安全性分析[J].癌症进展,2022,20(20):2095-2097.
[5] MOTZER R J, JONASCH E, BOYLE S, et al. NCCN guidelines insights: kidney cancer, version 1.2021[J].J Natl Compr Canc Netw,2020,18(9):1160-1170.
[6] SCHWARTZ L H, SEYMOUR L, LITIERE S, et al. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group[J].Eur J Cancer,2016,62(3):138-145.
[7] KLUETZ P G, CHINGOS D T, BASCH E M, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events[J].Am Soc Clin Oncol Educ Book,2016,35(1):67-73.
[8] LIU K, GAO R, WU H, et al. Single-cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma[J].J Cell Mol Med,2021,25(9):4260-4274.
[9] 苗陈岿,吴嘉进,卜恒涛,等. 细胞分裂周期蛋白25同源蛋白C调控肾细胞癌进展与舒尼替尼治疗敏感性[J].中华实验外科杂志,2022,39(7):1341-1344.
[10] 罗详冲,王周清,李琼艳,等. PD-1抑制剂替雷利珠单抗治疗晚期恶性肿瘤的药理作用与临床评价[J].协和医学杂志,2022,13(4):679-686.
[11] 刘郴郴,宋正帅,章小平. 肾透明细胞癌舒尼替尼耐药的分子标志物筛选及相关生物学功能分析[J].华中科技大学学报(医学版),2021,50(2):142-151.
[12] DELEUZE A, SAOUT J, DUGAY F, et al. Immunotherapy in renal cell carcinoma: the future is now[J].Int J Mol Sci,2020,21(7):2532.
[13] 张嘉琪,蒋俊玲,潘世杰,等. 千金子二萜醇通过NF-κB通路影响肾癌小鼠MMP-2、MMP-9的表达[J].中国老年学杂志,2021,41(9):1896-1900.
[14] 张娜,刘相良,徐志强,等. 肿瘤抗血管生成及其与免疫治疗关系的研究进展[J].吉林大学学报(医学版),2021,47(4):1056-1063. |
|
|
|
2024, Vol. 41 
